Breaking News Instant updates and real-time market news.

SRE

Sempra Energy

$137.17

-0.52 (-0.38%)

06:35
08/13/19
08/13
06:35
08/13/19
06:35

Sempra Energy initiated with an Equal Weight at Barclays

Barclays analyst Eric Beaumont started Sempra Energy with an Equal Weight rating and $142 price target. Sempra represents an attractive opportunity to gain exposure to a "top-tier" management team and the best parts of North American energy, Beaumont tells investors in a research note. However, the stock's outperformance year-to-date has brought shares to fair value, adds the analyst.

SRE Sempra Energy
$137.17

-0.52 (-0.38%)

04/16/19
ARGS
04/16/19
NO CHANGE
Target $142
ARGS
Buy
Sempra Energy price target raised to $142 from $130 at Argus
Argus analyst Jacob Kilstein raised his price target on Sempra Energy to $142 and kept his Buy rating, citing the management's forecast of annual earnings accretion of 10c-20c from the company's recent purchase of a majority stake in Texas's Oncor, favorable regulations at its California utilities, and investments in its Mexican midstream infrastructure. While Sempra Energy stock is trading at 21.8-times his expected FY19 earnings vs. 19.6-times peer group average, Kilstein believes that its premium valuation is warranted by the company's "above-peer-average sales growth, margin expansion, and increasing earnings."
06/04/19
KEYB
06/04/19
INITIATION
Target $151
KEYB
Overweight
Sempra Energy initiated with an Overweight at KeyBanc
KeyBanc analyst Sophie Karp started Sempra Energy with an Overweight rating and $151 price target. The analyst believes the company has a "cleaner structure" and higher earnings quality following the sales of non-core businesses in 2018.
06/27/19
BOFA
06/27/19
DOWNGRADE
BOFA
Neutral
Sempra Energy downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst Julien Dumoulin-Smith downgraded Sempra Energy to Neutral with a $142 price target citing share outperformance and moderating expectations on expedited CA legislation by the July 12 deadline combined with a potential credit downgrade.
06/27/19
06/27/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. FactSet (FDS) downgraded to Sell from Neutral at Goldman Sachs with analyst George Tong saying he believes FactSet faces "secular challenges" in the financial services end-market due to the implementation of MiFID II and the ongoing shift from active to passive asset management. 2. Travelers (TRV) downgraded to Sell from Hold at Deutsche Bank with analyst Joshua Shanker saying the commercial Property & Casualty sector is "largely overvalued" due to an intra-sector exodus from more rate-sensitive financials into P&C insurance stocks. 3. Sempra Energy (SRE) downgraded to Neutral from Buy at BofA/Merrill with analyst Julien Dumoulin-Smith citing share outperformance and moderating expectations on expedited CA legislation by the July 12 deadline combined with a potential credit downgrade. 4. W. R. Berkley (WRB) downgraded to Sell from Hold at Deutsche Bank with analyst Joshua Shanker saying investors are mistaking the appreciation in Property and Casualty insurance stocks as the "fruit of renewal rate pricing increases in the P&C market." 5. Ross Stores (ROST) and Nordstrom (JWN) downgraded to Sell from Neutral at Goldman Sachs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

NCR

NCR Corp.

$32.85

-0.26 (-0.79%)

07:59
09/18/19
09/18
07:59
09/18/19
07:59
Initiation
NCR Corp. initiated  »

NCR Corp. initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

ALNA

Allena Pharmaceuticals

$4.20

-0.035 (-0.83%)

07:55
09/18/19
09/18
07:55
09/18/19
07:55
Conference/Events
Allena Pharmaceuticals to hold a KOL breakfast meeting »

Management hosts a Key…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 18

    Sep

  • 24

    Sep

AAPL

Apple

$220.77

0.89 (0.40%)

07:52
09/18/19
09/18
07:52
09/18/19
07:52
Recommendations
Apple analyst commentary  »

Apple iPhone launch could…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVP

Avon Products

$4.79

0.09 (1.91%)

07:52
09/18/19
09/18
07:52
09/18/19
07:52
Hot Stocks
Avon Products announces launch of new skincare and make-up brand 'Distillery' »

Avon Products announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSM

TSMC

$45.15

0.55 (1.23%)

, AMD

AMD

$31.00

0.17 (0.55%)

07:51
09/18/19
09/18
07:51
09/18/19
07:51
Periodicals
TSMC extends production lead time for 7nm chip capacity, DIgiTimes reports »

TSMC (TSM) is extending…

TSM

TSMC

$45.15

0.55 (1.23%)

AMD

AMD

$31.00

0.17 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

CBRL

Cracker Barrel

$167.79

2.84 (1.72%)

07:50
09/18/19
09/18
07:50
09/18/19
07:50
Recommendations
Cracker Barrel analyst commentary  »

Cracker Barrel price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:50
09/18/19
09/18
07:50
09/18/19
07:50
General news
U.S. MBA reported mortgage applications dipped -0.1% in the September 13 week »

U.S. MBA reported…

AKTS

Akoustis

$7.90

0.1 (1.28%)

07:48
09/18/19
09/18
07:48
09/18/19
07:48
Downgrade
Akoustis rating change  »

Northland downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 12

    Nov

ACHV

Achieve Life Sciences

$2.23

-0.03 (-1.33%)

07:46
09/18/19
09/18
07:46
09/18/19
07:46
Conference/Events
Achieve Life Sciences to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 24

    Sep

CBWTF

Auxly Cannabis

$0.00

(0.00%)

07:45
09/18/19
09/18
07:45
09/18/19
07:45
Hot Stocks
Auxly Cannabis announces Canadian brokerage agreement with Kindred Partners »

Auxly Cannabis Group and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IOTS

Adesto Technologies

$10.63

-0.66 (-5.85%)

07:45
09/18/19
09/18
07:45
09/18/19
07:45
Initiation
Adesto Technologies initiated  »

Adesto Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCE

Spark Therapeutics

$104.41

-0.41 (-0.39%)

07:43
09/18/19
09/18
07:43
09/18/19
07:43
Hot Stocks
Spark Therapeutics, paralympic skier partner for genetic testing awareness »

Spark Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KLAC

KLA-Tencor

$152.55

1.38 (0.91%)

07:42
09/18/19
09/18
07:42
09/18/19
07:42
Recommendations
KLA-Tencor analyst commentary  »

KLA-Tencor price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VTVT

vTv Therapeutics

$1.73

-0.045 (-2.54%)

07:40
09/18/19
09/18
07:40
09/18/19
07:40
Hot Stocks
vTv Therapeutics presents additional data from Phase 2 Simplici-T1 study »

vTv Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Oct

07:40
09/18/19
09/18
07:40
09/18/19
07:40
General news
Treasury Market Outlook: yields extended declines overnight »

Treasury Market Outlook:…

GSK

GlaxoSmithKline

$41.10

0.49 (1.21%)

07:38
09/18/19
09/18
07:38
09/18/19
07:38
Conference/Events
FDA Non-Prescription Drugs Advisory Committee to hold a meeting »

The Committee discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 24

    Sep

  • 27

    Sep

  • 02

    Oct

OPGN

OpGen

$7.02

-0.07 (-0.99%)

07:37
09/18/19
09/18
07:37
09/18/19
07:37
Hot Stocks
OpGen says Curetis collaborator obtains option to license ARESdb »

OpGen reported an update…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLK

BlackRock

$438.98

3.12 (0.72%)

, TROW

T. Rowe Price

$117.98

1.1 (0.94%)

07:37
09/18/19
09/18
07:37
09/18/19
07:37
Recommendations
BlackRock, T. Rowe Price analyst commentary  »

BlackRock's…

BLK

BlackRock

$438.98

3.12 (0.72%)

TROW

T. Rowe Price

$117.98

1.1 (0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 26

    Sep

  • 27

    Oct

AXDX

Accelerate Diagnostics

$21.30

1.85 (9.51%)

07:36
09/18/19
09/18
07:36
09/18/19
07:36
Hot Stocks
Accelerate Diagnostics reports 'positive' results in three Pheno system studies »

Accelerate Diagnostics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

ADBE

Adobe

$284.59

1.54 (0.54%)

, WWE

WWE

$75.88

1.73 (2.33%)

07:35
09/18/19
09/18
07:35
09/18/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

ADBE

Adobe

$284.59

1.54 (0.54%)

WWE

WWE

$75.88

1.73 (2.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

BIIB

Biogen

$238.65

2.54 (1.08%)

07:34
09/18/19
09/18
07:34
09/18/19
07:34
Hot Stocks
Biogen to present new data from SHINE study on safety and efficacy of SPINRAZA »

Biogen announced updates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

IAC

IAC

$236.73

7.5 (3.27%)

, MTCH

Match Group

$79.70

3 (3.91%)

07:33
09/18/19
09/18
07:33
09/18/19
07:33
Recommendations
IAC, Match Group, Angi Homeservices analyst commentary  »

IAC spinoffs could unlock…

IAC

IAC

$236.73

7.5 (3.27%)

MTCH

Match Group

$79.70

3 (3.91%)

ANGI

Angi Homeservices

$7.60

-0.31 (-3.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Oct

EFX

Equifax

$141.79

1.78 (1.27%)

07:32
09/18/19
09/18
07:32
09/18/19
07:32
Hot Stocks
Equifax partners with Urjanet for utility payment data sharing platform »

Equifax and Urjanet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 13

    Nov

BHVN

Biohaven Pharmaceutical

$47.24

-0.8 (-1.67%)

07:32
09/18/19
09/18
07:32
09/18/19
07:32
Hot Stocks
Biohaven Pharmaceutical's verdiperstat selected for ALS platform trial »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$238.65

2.54 (1.08%)

07:32
09/18/19
09/18
07:32
09/18/19
07:32
Hot Stocks
Biogen to initiate DEVOTE clinical trial evaluating higher dose of SPINRAZA »

Biogen announced updates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.